 AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 GLOBE NEWSWIRE -- Shattuck Labs, Inc. NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022. 